Company intelligence / Profile preview
ImevaX
Munich, Bavaria, Germanyimevax.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ImevaX has developed a pipeline focused on combating chronic and hospital-acquired infections through specific vaccines and diagnostics. Its lead vaccine candidate IMX101 targets H. pylori by neutralizing its immune evasion mechanism, with preclinical/early clinical progress reported. The company also markets Pylori DuoTect®, a rapid point-of-care test for H. pylori antibodies that delivers results within 20 minutes.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccinesin vitro diagnostics (rapid antibody tests)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Institute of Microbiology at Technical University Munich (TUM)
Beyond the preview
Go deeper on ImevaX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImevaX.